Drug Trial Radar · NCT05901714
A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam
Last checked: Nov 19, 2026Latest source record: Aug 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
65
Actual
Start
Jun 14, 2023
Primary completion
Apr 11, 2024
Study completion Apr 11, 2024
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jun 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will consist of 2 parts. The study will evaluate whether administration of phenytoin impacts the single-dose drug levels of afimetoran and BMT-271199 (Part 1) and will evaluate whether multiple administrations of afimetoran impact the drug levels of midazolam and 1-hydroxymidazolam (Part 2).
Conditions
- Healthy Participants
Interventions
AfimetoranDrug
Specified dose on specified days
PhenytoinDrug
Specified dose on specified days
MidazolamDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax)Time frame: Up to 53 days
- Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC[0-T])Time frame: Up to 53 days
- Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])Time frame: Up to 53 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Local Institution - 0001
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.